Developer docs
API playgroundTry for free, no card

Search company profiles

VHL Alliance

Full company profile

uuid000j5j6

Namestring
VHL Alliance
Websiteurl
vhl.org
Company typeenum
Private
Founded yearint
1993
Descriptiontext

VHL Alliance is a nonprofit patient advocacy organization founded in 1993 and headquartered in Boston, Massachusetts. According to its self-description, the organization provides awareness, diagnosis, and treatment support aimed at improving the quality of life for people affected by Von Hippel-Lindau (VHL) disease, a rare inherited genetic disorder that predisposes patients to tumors and cysts across multiple organ systems. The organization operates with a very small team of 1-10 employees, consistent with a lean rare-disease advocacy model reliant on a core staff supplemented by volunteer medical advisors and community members.

The organization is structured as a 501(c)(3)-style nonprofit (company_type: non_profit) and operates as a private entity with no public listing. No revenue model, pricing structure, product portfolio, technology stack, or strategic initiative details were available in the scraped source content — the firm's public web properties returned only loading/verification pages during data collection. As a result, the actual breadth of programmatic offerings (patient registry, clinical trial navigation, physician education, research grants, support groups) cannot be confirmed from the input, though these are typical for organizations in this category.

The competitive context is defined by the extreme rarity of VHL (estimated prevalence of 1 in 36,000 births), which means the addressable patient population is small but highly motivated and concentrated. VHL Alliance's longevity (30+ years) and Boston location — a major US biotech and academic medical hub — are its most observable structural assets. However, the absence of disclosed financials, partnerships, leadership roster, or measurable programmatic output in the input limits any deeper operational assessment.

Short descriptiontext

VHL Alliance is a Boston-based nonprofit founded in 1993 that supports people affected by Von Hippel-Lindau disease through awareness, diagnosis, and treatment advocacy to improve patient quality of life.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease advocacy, patient support services, genetic disorder awareness, disease information resources, community health support
Industry1 code
PRIMARYBPADAIAL
Community Health, Health Promotion & Behavior Change (SBCC)
NAICS code2 codes
  • Social Assistance624
  • Other Individual and Family Services62419
SIC code2 codes
  • Services-Social Services8300
  • Services-Misc Health & Allied Services, Nec8090
Product category
Rare Disease Patient Advocacy
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

VHL Alliance is a non-profit organization that provides awareness, diagnosis support, and treatment-related resources for individuals and families affected by Von Hippel-Lindau (VHL) disease. It works to improve the quality of life for the VHL patient community through advocacy, education, and community support. Its offerings are patient- and community-focused rather than commercial products.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1VHL Disease Awareness Programs
CategoryPatient advocacy and awareness
Description

Awareness and education services focused on Von Hippel-Lindau disease for patients, families, and the broader public. Aims to increase recognition and understanding of the rare genetic disorder.

2VHL Diagnosis Support
CategoryPatient advocacy and awareness
Description

Support resources to help patients and families navigate the diagnostic process for Von Hippel-Lindau disease. Targeted at individuals suspected of or newly affected by the condition.

3VHL Treatment Resources
CategoryPatient advocacy and awareness
Description

Treatment-related information and resources for individuals affected by Von Hippel-Lindau disease. Supports patients in accessing appropriate care and treatment options.

4Quality of Life Support for VHL Community
CategoryCommunity support services
Description

Programs and support services aimed at improving the quality of life for people affected by Von Hippel-Lindau disease, including community and patient support resources.

No data
Peers8 records
1VHL Canada (Canadian VHL Alliance)
TypeRegional player
Description

Canadian sister organization serving VHL patients in Canada. Comparable because it operates the same disease-specific advocacy model in a different geography and occasionally collaborates with VHL Alliance on cross-border initiatives.

TypeDirect peer
Description

Non-profit focused on transforming health through genetics and supporting condition-specific advocacy organizations. Directly comparable as it serves a similar role for genetic-condition patient communities and provides infrastructure for groups like VHL Alliance.

TypeDirect peer
Description

Patient advocacy and research-funding non-profit focused on neurofibromatosis. Comparable as a similarly-sized rare-genetic-disease advocacy organization that combines awareness, research support, and patient services.

TypeEmerging player
Description

Non-profit supporting patients and families affected by rare diseases through research and care programs. Comparable in advocacy mission and small-team operating profile.

TypeBroad incumbent
Description

US-based umbrella advocacy organization for the entire rare-disease community. NORD is comparable because it competes for the same donor and grant dollars and overlaps in patient advocacy for conditions like VHL.

TypeBroad incumbent
Description

National non-profit providing case management and financial assistance to patients with chronic, debilitating illnesses. Comparable as it serves a similar patient-support function for those with rare and serious conditions.

7Tuberous Sclerosis Alliance
TypeDirect peer
Description

Non-profit advocacy organization for tuberous sclerosis complex, another rare genetic tumor-predisposition syndrome. Closely comparable in mission, scope, and operating model to VHL Alliance.

TypeOthers
Description

Major US non-profit addressing kidney disease, which is clinically relevant for VHL patients who develop renal cell carcinoma and renal cysts. Comparable because it competes for similar patient-education and screening-program funding.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VHL Alliance

Rare Disease Patient Advocacyvhl.org

VHL Alliance is a Boston-based nonprofit founded in 1993 that supports people affected by Von Hippel-Lindau disease through awareness, diagnosis, and treatment advocacy to improve patient quality of life.

What VHL Alliance does

VHL Alliance is a nonprofit patient advocacy organization founded in 1993 and headquartered in Boston, Massachusetts. According to its self-description, the organization provides awareness, diagnosis, and treatment support aimed at improving the quality of life for people affected by Von Hippel-Lindau (VHL) disease, a rare inherited genetic disorder that predisposes patients to tumors and cysts across multiple organ systems. The organization operates with a very small team of 1-10 employees, consistent with a lean rare-disease advocacy model reliant on a core staff supplemented by volunteer medical advisors and community members.

The organization is structured as a 501(c)(3)-style nonprofit (company_type: non_profit) and operates as a private entity with no public listing. No revenue model, pricing structure, product portfolio, technology stack, or strategic initiative details were available in the scraped source content — the firm's public web properties returned only loading/verification pages during data collection. As a result, the actual breadth of programmatic offerings (patient registry, clinical trial navigation, physician education, research grants, support groups) cannot be confirmed from the input, though these are typical for organizations in this category.

The competitive context is defined by the extreme rarity of VHL (estimated prevalence of 1 in 36,000 births), which means the addressable patient population is small but highly motivated and concentrated. VHL Alliance's longevity (30+ years) and Boston location — a major US biotech and academic medical hub — are its most observable structural assets. However, the absence of disclosed financials, partnerships, leadership roster, or measurable programmatic output in the input limits any deeper operational assessment.

VHL Alliance firmographics

Firmographics
Name
VHL Alliance
Website
https://vhl.org
Company type
Private
Founded year
1993
Headcount range
11–50 employees
Short description
VHL Alliance is a Boston-based nonprofit founded in 1993 that supports people affected by Von Hippel-Lindau disease through awareness, diagnosis, and treatment advocacy to improve patient quality of life.
Ownership category
akta.pro rank

VHL Alliance industry classification

Industry
Product category
Rare Disease Patient Advocacy
NAICS
Social Assistance (624), Other Individual and Family Services (62419)
SIC
Services-Social Services (8300), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPADAIAL
Community Health, Health Promotion & Behavior Change (SBCC)

Keywords

  • Rare disease advocacy
  • Patient support services
  • Genetic disorder awareness
  • Disease information resources
  • Community health support

Where VHL Alliance is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

VHL Alliance business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

VHL Alliance product offering

Product offering

Core offering

VHL Alliance is a non-profit organization that provides awareness, diagnosis support, and treatment-related resources for individuals and families affected by Von Hippel-Lindau (VHL) disease. It works to improve the quality of life for the VHL patient community through advocacy, education, and community support. Its offerings are patient- and community-focused rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

  • VHL Disease Awareness Programs Awareness and education services focused on Von Hippel-Lindau disease for patients, families, and the broader public. Aims to increase recognition and understanding of the rare genetic disorder.
  • VHL Diagnosis Support Support resources to help patients and families navigate the diagnostic process for Von Hippel-Lindau disease. Targeted at individuals suspected of or newly affected by the condition.
  • VHL Treatment Resources Treatment-related information and resources for individuals affected by Von Hippel-Lindau disease. Supports patients in accessing appropriate care and treatment options.
  • Quality of Life Support for VHL Community Programs and support services aimed at improving the quality of life for people affected by Von Hippel-Lindau disease, including community and patient support resources.

Companies that use VHL Alliance

Customer profile

Ideal customer profiles1 record

VHL Alliance technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

VHL Alliance competitors and assessment

Company assessment

Regional players

  • VHL Canada (Canadian VHL Alliance): Canadian sister organization serving VHL patients in Canada. Comparable because it operates the same disease-specific advocacy model in a different geography and occasionally collaborates with VHL Alliance on cross-border initiatives.

Direct peers

  • Genetic Alliance: Non-profit focused on transforming health through genetics and supporting condition-specific advocacy organizations. Directly comparable as it serves a similar role for genetic-condition patient communities and provides infrastructure for groups like VHL Alliance.
  • Children's Tumor Foundation: Patient advocacy and research-funding non-profit focused on neurofibromatosis. Comparable as a similarly-sized rare-genetic-disease advocacy organization that combines awareness, research support, and patient services.
  • Tuberous Sclerosis Alliance: Non-profit advocacy organization for tuberous sclerosis complex, another rare genetic tumor-predisposition syndrome. Closely comparable in mission, scope, and operating model to VHL Alliance.

Emerging players

  • Rare Disease Foundation: Non-profit supporting patients and families affected by rare diseases through research and care programs. Comparable in advocacy mission and small-team operating profile.

Broad incumbents

  • National Organization for Rare Disorders (NORD): US-based umbrella advocacy organization for the entire rare-disease community. NORD is comparable because it competes for the same donor and grant dollars and overlaps in patient advocacy for conditions like VHL.
  • Patient Advocate Foundation: National non-profit providing case management and financial assistance to patients with chronic, debilitating illnesses. Comparable as it serves a similar patient-support function for those with rare and serious conditions.

Others

  • National Kidney Foundation: Major US non-profit addressing kidney disease, which is clinically relevant for VHL patients who develop renal cell carcinoma and renal cysts. Comparable because it competes for similar patient-education and screening-program funding.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

VHL Alliance social profiles

Digital presence

VHL Alliance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VHL Alliance leadership team

Management profile

Number of profiles

VHL Alliance funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VHL Alliance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VHL Alliance

What does VHL Alliance do?

VHL Alliance is a non-profit organization that provides awareness, diagnosis support, and treatment-related resources for individuals and families affected by Von Hippel-Lindau (VHL) disease. It works to improve the quality of life for the VHL patient community through advocacy, education, and community support. Its offerings are patient- and community-focused rather than commercial products.

When was VHL Alliance founded?

VHL Alliance was founded in 1993. It employs 11 to 50 people.

Where is VHL Alliance based?

VHL Alliance is headquartered in Boston, United States, in the North America region.

Who are VHL Alliance's main competitors?

VHL Canada (Canadian VHL Alliance) is listed as a regional player. Direct peers are Genetic Alliance, Children's Tumor Foundation and Tuberous Sclerosis Alliance. Rare Disease Foundation is listed as an emerging player. Broad incumbents are National Organization for Rare Disorders (NORD) and Patient Advocate Foundation. National Kidney Foundation is listed as an others.

Does VHL Alliance have an API?

No public API is recorded for VHL Alliance.

What industry is VHL Alliance in?

VHL Alliance's product category is Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPADAIAL, Community Health, Health Promotion & Behavior Change (SBCC). Its NAICS code is 624 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCURE Media Group Strengthens Strategic Alliance Partnership Program With the Addition of Five New PartnersCURE Media Group announced the expansion of its Strategic Alliance Partnership program with five new nonprofit cancer organizations: ALK Positive, Brain Tumor Network, Head and Neck Cancer Alliance, KidneyCAN, and VHL Alliance. The partnerships aim to raise awareness, support patients, and advance cancer education by sharing information and highlighting different cancer communities through CURE Media Group's multimedia platform. Mike Hennessy Jr., president and CEO of MJH Life Sciences, stated that the partnerships would increase visibility and presence in the oncology landscape while supporting research and education.PR NewswireSpanish Language Version of Pioneering Patient History Study LaunchedThe VHL Alliance launched a Spanish-language version of its MyVHL patient history registry, developed in collaboration with NORD and input from the National Institutes of Health. This expansion makes the patient-driven database immediately accessible to Spanish-speaking patients and researchers globally, aiming to accelerate research into von Hippel-Lindau disease.PR NewswireVHL Mobile App Challenge Winner AnnouncedThe VHL Alliance announced Cody Craig from The Ohio State University as the winner of its VHL Mobile App Challenge, which received nearly two dozen entries from top US universities. Craig developed a free mobile app for iOS to help patients, caregivers, and healthcare professionals manage care for von Hippel-Lindau, a genetic cancer condition. As recognition, Craig will receive a one-time grant of $5,000 funded by an anonymous donor.PR NewswireElsevier Collaborates with VHL Alliance on PracticeUpdateElsevier and VHL Alliance launched a PracticeUpdate module on von Hippel-Lindau disease, a rare condition affecting one in 36,000 U.S. people. The free resource includes expert opinions, video interviews, and tumor board discussions. The collaboration aims to improve diagnosis and treatment for VHL patients.PR NewswireElsevier Collaborates with VHL Alliance on PracticeUpdateElsevier and the VHL Alliance have collaborated to launch a new content module on PracticeUpdate focused on von Hippel-Lindau Disease. This initiative aims to provide physicians with up-to-date research, expert opinions, and case discussions to improve diagnosis and treatment of the rare condition.GlobeNewswireMay is VHL Awareness MonthThe VHL Family Alliance launched its May awareness campaign "Early Detection Empowers Us" to advocate early detection of Von Hippel-Lindau disease tumors. VHL affects about one in 32,000 people worldwide, with no cure currently available. The organization works to improve diagnosis, treatment, and patient support.